Sage Therapeutics to end Huntington's disease trial after key therapy fails again
Portfolio Pulse from
Sage Therapeutics has decided to terminate its trial for the therapy dalzanemdor in treating Huntington's disease after it failed to meet its goals. This marks the third failure for the therapy, which also did not succeed in trials for Alzheimer's disease.
November 20, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has ended its trial for dalzanemdor in Huntington's disease after repeated failures, impacting its stock negatively.
The termination of the trial for dalzanemdor, after multiple failures, is likely to negatively impact Sage Therapeutics' stock as it indicates setbacks in their product pipeline and potential revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100